Navigation Links
The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics' Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977
Date:8/19/2011

WHITE PLAINS, N.Y., Aug. 19, 2011 /PRNewswire/ -- Today the Food and Drug Administration (FDA) approved Seattle Genetics' Adcetris to treat two types of rare blood cancers – Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL).

(Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO)

The drug is approved for Hodgkin lymphoma patients after failure of a stem cell transplant or two chemotherapy treatments and for ALCL patients after failure of at least one multi-agent chemotherapy treatment.

"This is a great advance for patients battling both of these diseases," said Hildy Dillon, Senior Vice President of Patient Services for The Leukemia & Lymphoma Society. "These are both considered very curable diseases but there is a population of patients from both diseases for whom treatment has not been effective."

Hodgkin lymphoma has an 86 percent survival and ALCL has an 80 percent cure rate.

"But for those people who don't respond well these can be very difficult cancers to cure. This advance gives new hope to that group of patients," Dillon said.

Dillon added that Seattle Genetics should be commended for investing in a therapy for a very small subgroup of patients who don't respond to standard therapy and for whom there were very limited options until now.

There are nearly 9,000 new cases of Hodgkin lymphoma diagnosed each year and 3,000 new cases of ALCL, and both diseases primarily impact children in their late teens and young adults.  Adcetris is a targeted therapy linking a tumor-targeting antibody to a chemotherapy drug with the goal of limiting side effects.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.LLS.org.

For LLS Contact:
Andrea Greif
Work: 914-821-8958
Cell: 914-772-3027
andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perdue Kidd & Vickery Files Lawsuit Against Abbott Laboratories for Inadequate Leukemia and Cancer Warning
2. Recent Study Shows Leukothera™ Combined with Other Agents Has Enhanced Anti-Leukemia Effects
3. Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia
4. Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders
5. Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
6. Medco Partners With MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
7. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides
8. Reportlinker Adds Triple Analysis: Breast Cancer, Leukemia and Cancer Vaccines
9. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer
10. Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis
11. Reportlinker Adds Triple Analysis: Colorectal Cancer, Leukemia and Apoptosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016 ALSP, Inc. announced that ... as Consultant for Medical Affairs in preparation for its move ... Pierschbacher , PhD, CEO, stated, "We are pleased to welcome ... forward to working with an individual of such practical knowledge ... forward to drawing deeply on his broad experience and success ...
(Date:2/10/2016)... -- --> --> ... Equipment Market by Package Type (Blister, Strip, Bottle, Tube, ... (Tablet, Powder, Cream, Syrup, Aseptic Liquid, Aerosol) - Global ... during the forecast period of 2015 to 2020. The ... 6.9% during the forecast period to reach USD 7.24 ...
(Date:2/10/2016)... , Feb. 9, 2016 CTI ... today provided an update regarding the clinical studies ... ("IND") application for pacritinib. Following the issuance of ... the partial clinical hold issued by the U.S. ... studies, the Company received an oral communication from ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing ... February 2016. Each webinar features a dynamic expert and thoughtful presentation to give ... patients and facilities. Both events are free to attend, but registration is ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... (VRI) within Healthcare, recently partnered with Heart City Health Center to ... nearly 23 years, Heart City Health Center has provided the Elkhart community with ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced on Wednesday that ... an emergency medicine professional association, to support the organization's newly established physician group ... of Emergency Medicine, or AAEM, seeks to empower emergency physicians to control their ...
(Date:2/10/2016)... ... 10, 2016 , ... Compliancy Group LLC is pleased to ... throughout the country. The Guard was specifically designed to handle each element required ... regulatory updates, and compliance coaching. , In addition to meeting the compliance needs ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... charity program created to assist the local community. Pledging to select a new ... nonprofit organizations in the area. Their goal is to bring community awareness to ...
Breaking Medicine News(10 mins):